These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1348 related articles for article (PubMed ID: 33736526)

  • 1. Tocilizumab for the Critically Ill With Severe COVID-19: A Community Hospital Case Series.
    McKenzie MG; Lee YM; Mathew J; Anderson M; Vo AT; Akinyele S; Narayanan M
    J Pharm Pract; 2022 Aug; 35(4):587-592. PubMed ID: 33736526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19.
    Gupta S; Wang W; Hayek SS; Chan L; Mathews KS; Melamed ML; Brenner SK; Leonberg-Yoo A; Schenck EJ; Radbel J; Reiser J; Bansal A; Srivastava A; Zhou Y; Finkel D; Green A; Mallappallil M; Faugno AJ; Zhang J; Velez JCQ; Shaefi S; Parikh CR; Charytan DM; Athavale AM; Friedman AN; Redfern RE; Short SAP; Correa S; Pokharel KK; Admon AJ; Donnelly JP; Gershengorn HB; Douin DJ; Semler MW; Hernán MA; Leaf DE;
    JAMA Intern Med; 2021 Jan; 181(1):41-51. PubMed ID: 33080002
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy.
    Grasselli G; Zangrillo A; Zanella A; Antonelli M; Cabrini L; Castelli A; Cereda D; Coluccello A; Foti G; Fumagalli R; Iotti G; Latronico N; Lorini L; Merler S; Natalini G; Piatti A; Ranieri MV; Scandroglio AM; Storti E; Cecconi M; Pesenti A;
    JAMA; 2020 Apr; 323(16):1574-1581. PubMed ID: 32250385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tocilizumab treatment in critically ill patients with COVID-19: A retrospective observational study.
    Huang E; Isonaka S; Yang H; Salce E; Rosales E; Jordan SC
    Int J Infect Dis; 2021 Apr; 105():245-251. PubMed ID: 33609773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tocilizumab as a Therapeutic Agent for Critically Ill Patients Infected with SARS-CoV-2.
    Petrak RM; Skorodin NC; Van Hise NW; Fliegelman RM; Pinsky J; Didwania V; Anderson M; Diaz M; Shah K; Chundi VV; Hines DW; Harting BP; Sidwha K; Yu B; Brune P; Owaisi A; Beezhold D; Kent J; Vais D; Han A; Gowda N; Sahgal N; Silverman J; Stake J; Nepomuceno J; Heddurshetti R
    Clin Transl Sci; 2021 Nov; 14(6):2146-2151. PubMed ID: 32918792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial.
    Maes B; Bosteels C; De Leeuw E; Declercq J; Van Damme K; Delporte A; Demeyere B; Vermeersch S; Vuylsteke M; Willaert J; Bollé L; Vanbiervliet Y; Decuypere J; Libeer F; Vandecasteele S; Peene I; Lambrecht B
    Trials; 2020 Jun; 21(1):468. PubMed ID: 32493441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial.
    Salvarani C; Dolci G; Massari M; Merlo DF; Cavuto S; Savoldi L; Bruzzi P; Boni F; Braglia L; Turrà C; Ballerini PF; Sciascia R; Zammarchi L; Para O; Scotton PG; Inojosa WO; Ravagnani V; Salerno ND; Sainaghi PP; Brignone A; Codeluppi M; Teopompi E; Milesi M; Bertomoro P; Claudio N; Salio M; Falcone M; Cenderello G; Donghi L; Del Bono V; Colombelli PL; Angheben A; Passaro A; Secondo G; Pascale R; Piazza I; Facciolongo N; Costantini M;
    JAMA Intern Med; 2021 Jan; 181(1):24-31. PubMed ID: 33080005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tocilizumab in critically ill COVID-19 patients: An observational study.
    Mushtaq MZ; Mahmood SBZ; Almas A; Ather Wasti S; Ahsan Ali S
    Int Immunopharmacol; 2022 Jan; 102():108384. PubMed ID: 34838490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The COVIRL002 Trial-Tocilizumab for management of severe, non-critical COVID-19 infection: A structured summary of a study protocol for a randomised controlled trial.
    Cotter A; Wallace D; McCarthy C; Feeney E; O'Neill L; Stack J; McCarthy G; Hussain R; Alvarez Barco E; Doran P; Mallon P
    Trials; 2020 Sep; 21(1):758. PubMed ID: 32883328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic efficacy, mechanical ventilation, length of hospital stay, and mortality rate in severe COVID-19 patients treated with tocilizumab.
    Sarhan RM; Madney YM; Abou Warda AE; Boshra MS
    Int J Clin Pract; 2021 Jun; 75(6):e14079. PubMed ID: 33550688
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Off-label tocilizumab and adjuvant iron chelator effectiveness in a group of severe COVID-19 pneumonia patients: A single center experience.
    Birlutiu V; Birlutiu RM; Chicea L
    Medicine (Baltimore); 2021 May; 100(18):e25832. PubMed ID: 33950993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Tocilizumab on Inflammatory Markers and Oxygen Status in Severe COVID-19 Patients: A Single Centre Retrospective Study.
    Sharma A; Nathiya D; Suman S; Bareth H; Singh M; Sharma E
    Infect Disord Drug Targets; 2022; 22(5):e210222201328. PubMed ID: 35189802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant Tocilizumab in the Treatment of Patients with Moderate to Severe COVID-19 Pneumonia: An Observational Study.
    Shastri M; Raval DM; Rathod VM; Patel D
    J Assoc Physicians India; 2022 Jan; 70(1):11-12. PubMed ID: 35062798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tocilizumab in the treatment of critical COVID-19 pneumonia: A retrospective cohort study of mechanically ventilated patients.
    Fisher MJ; Marcos Raymundo LA; Monteforte M; Taub EM; Go R
    Int J Infect Dis; 2021 Feb; 103():536-539. PubMed ID: 33333252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk Factors Associated With Mortality Among Patients With COVID-19 in Intensive Care Units in Lombardy, Italy.
    Grasselli G; Greco M; Zanella A; Albano G; Antonelli M; Bellani G; Bonanomi E; Cabrini L; Carlesso E; Castelli G; Cattaneo S; Cereda D; Colombo S; Coluccello A; Crescini G; Forastieri Molinari A; Foti G; Fumagalli R; Iotti GA; Langer T; Latronico N; Lorini FL; Mojoli F; Natalini G; Pessina CM; Ranieri VM; Rech R; Scudeller L; Rosano A; Storti E; Thompson BT; Tirani M; Villani PG; Pesenti A; Cecconi M;
    JAMA Intern Med; 2020 Oct; 180(10):1345-1355. PubMed ID: 32667669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia.
    Capra R; De Rossi N; Mattioli F; Romanelli G; Scarpazza C; Sormani MP; Cossi S
    Eur J Intern Med; 2020 Jun; 76():31-35. PubMed ID: 32405160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tocilizumab in patients with severe COVID-19: A single-center observational analysis.
    Knorr JP; Colomy V; Mauriello CM; Ha S
    J Med Virol; 2020 Nov; 92(11):2813-2820. PubMed ID: 32628003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial.
    Hermine O; Mariette X; Tharaux PL; Resche-Rigon M; Porcher R; Ravaud P;
    JAMA Intern Med; 2021 Jan; 181(1):32-40. PubMed ID: 33080017
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A prospective, randomised, double blind placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia (TOC-COVID): A structured summary of a study protocol for a randomised controlled trial.
    Rilinger J; Kern WV; Duerschmied D; Supady A; Bode C; Staudacher DL; Wengenmayer T
    Trials; 2020 Jun; 21(1):470. PubMed ID: 32493514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 68.